Nurix Therapeutics, Inc. announced the appointments of Paula G. O?Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer of Nurix. Dr. O?Connor joined Nurix in September 2022 and most recently served as executive vice president and head of clinical development. She trained as a hematologist-oncologist and has more than 15 years of drug development expertise.

Prior to joining Nurix, Dr. O?Connor held senior level positions in clinical development and medical affairs at Protagonist Therapeutics, Oncopeptides, Inc., Coherus Biosciences, Medivation, Onyx, and Genentech. Dr. O?Connor completed her fellowships in hematology, oncology, and AIDS oncology at the combined programs of the Massachusetts General, Brigham and Women?s, and Dana Farber Cancer Institute. She holds a B.A. in psychology with a biology focus from Yale University and an M.D. from Stanford University.

Dr. Phiasivongsa joined Nurix in August 2022 and most recently served as executive vice president of technical operations. Prior to joining Nurix, he served as senior vice president, pharmaceutical development & manufacturing at Kronos Bio, where he led all CMC development, manufacturing, and supply chain-related activities. Before Kronos, Dr. Phiasivongsa served in senior CMC leadership roles at Principia Biopharma and Tobira Therapeutics.

Early in his career, he held positions in drug discovery, development, and manufacturing. He is listed on 32 U.S.-issued patents and more than 40 patent applications. Dr. Phiasivongsa earned his B.S. in biochemistry and Ph.D. in pharmaceutical and chemical sciences from the University of the Pacific, Stockton.